Stay updated on Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial page.

Latest updates to the Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe revision label changed from v3.6.4 to v3.6.5, signaling a new page version. This is a metadata update, not a modification to study data or content.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page revision has been updated from v3.6.3 to v3.6.4, indicating an incremental version update. It does not appear to alter study data or eligibility details.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page shows a new revision tag indicating an updated study record (v3.6.3), replacing the previous version (v3.6.2).SummaryDifference0.0%

- Check54 days agoChange DetectedRevision: v3.6.2 appears, replacing the previous v3.6.0. This indicates a minor, administrative update to the page template or related content rather than changes to the study data.SummaryDifference0.0%

- Check68 days agoChange DetectedRecruitment for the study is now closed, and new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) have been added to help users navigate the record. In addition, the Intervention/Treatment header formatting was updated and the page revision tag updated to v3.6.0.SummaryDifference0.4%

- Check75 days agoChange DetectedA new Revision: v3.5.5 tag was added and the previous Revision: v3.5.4 tag removed, indicating a minor page update.SummaryDifference0.0%

Stay in the know with updates to Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy of Rituximab & Pembrolizumab in Waldenström's Clinical Trial page.